Klaus Klumpp is a Co-Founder and President of Riboscience LLC, a biotechnology company involved in the discovery and development of cures for viral diseases and cancer. He previously served as Vice President, Discovery Research at Novira Therapeutics Inc., contributing to the development of new treatments for chronic Hepatitis B infection. Novira Therapeutics Inc. was acquired by Johnson & Johnson in 2015. Klaus led research and development activities at Roche in the area of infectious diseases between 1997 and 2013, most recently as Vice President andGlobal Head of Virology Discovery. He also held research fellow positions at GlaxoWellcome Research and Development, the European Molecular Biology Laboratory (EMBL) and the Max-Planck Institute for Biophysics. He serves as an advisor to Bioage Labs Inc., Biotron Ltd., The German Center for Infection Research (DZIF) and RESIST.